These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 1673972)
41. Growth hormone and its disorders. Ayuk J; Sheppard MC Postgrad Med J; 2006 Jan; 82(963):24-30. PubMed ID: 16397076 [TBL] [Abstract][Full Text] [Related]
42. Dynamic testing in the diagnosis and follow-up of patients with acromegaly. Wass JA J Endocrinol Invest; 2003; 26(7 Suppl):48-53. PubMed ID: 14604066 [TBL] [Abstract][Full Text] [Related]
43. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720 [TBL] [Abstract][Full Text] [Related]
44. [Treatment of acromegaly]. Halperin Rabinovich I Med Clin (Barc); 1988 Oct; 91(12):449-51. PubMed ID: 2905402 [No Abstract] [Full Text] [Related]
45. Somatostatin analogs in the treatment of acromegaly. Lamberts SW; Reubi JC; Krenning EP Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729 [TBL] [Abstract][Full Text] [Related]
46. Ectopic growth hormone releasing factor stimulates growth hormone release from human somatotroph adenomas in vitro. Webb CB; Thominet JL; Frohman LA J Clin Endocrinol Metab; 1983 Feb; 56(2):417-9. PubMed ID: 6130102 [TBL] [Abstract][Full Text] [Related]
47. [Management of acromegaly in 2003]. Bertherat J; Bouchard P; Chanson P; Benoît A; Bourgeon M; Brémont C; Kahal Z; Mathé C; Requeda E Ann Endocrinol (Paris); 2003 Apr; 64(2):I-IV. PubMed ID: 12773933 [No Abstract] [Full Text] [Related]
48. Choosing the best treatment for acromegaly. Christy NP JAMA; 1982 Mar; 247(9):1320. PubMed ID: 6121067 [No Abstract] [Full Text] [Related]
49. [Retrocession of acromegaly after radical excision of a voluminous, bifocal, endocrine tumor of the pancreas. Starting point for the discovery of growth hormone releasing factor]. Partensky C; Champetier P; Sassolas G; Chayvialle JA; Berger F; Trouillas J; Berger G Chirurgie; 1985; 111(3):207-14. PubMed ID: 3935398 [No Abstract] [Full Text] [Related]
50. Ectopic secretion of growth hormone-releasing hormone in man. Losa M; Schopohl J; von Werder K J Endocrinol Invest; 1993 Jan; 16(1):69-81. PubMed ID: 8445159 [No Abstract] [Full Text] [Related]
51. [Treatment of growth hormone secretion disorders]. Manojlović D Srp Arh Celok Lek; 1981; 109(5-6):723-9. PubMed ID: 7345615 [No Abstract] [Full Text] [Related]
56. Modern approaches to treating acromegaly. Turner HE; Wass JA QJM; 2000 Jan; 93(1):1-6. PubMed ID: 10623775 [No Abstract] [Full Text] [Related]
57. Acromegaly: treatment after 100 years. Wass JA BMJ; 1993 Dec; 307(6918):1505-6. PubMed ID: 8274912 [No Abstract] [Full Text] [Related]
58. Etiologic aspects and management of acromegaly. Taboada GF; van Haute FR; Corrêa LL; Casini AF; Gadelha MR Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):626-40. PubMed ID: 16444346 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Marzullo P; Ferone D; Di Somma C; Pivonello R; Filippella M; Lombardi G; Colao A Pituitary; 1999; 1(2):115-20. PubMed ID: 11081189 [TBL] [Abstract][Full Text] [Related]
60. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]